

## **Clinical Policy: Prednisone Delayed-Release (Rayos)**

Reference Number: CP.CPA.273

Effective Date: 11.16.16

Last Review Date: 11.25

Line of Business: Commercial

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

### **Description**

Delayed-release prednisone (Rayos<sup>®</sup>) is a corticosteroid.

### **FDA Approved Indication(s)**

Rayos is indicated:

- As an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation
- For the treatment of certain endocrine conditions
- For palliation of certain neoplastic conditions

### **Policy/Criteria**

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

It is the policy of health plans affiliated with Centene Corporation<sup>®</sup> that Rayos is **medically necessary** when the following criteria are met:

#### **I. Initial Approval Criteria**

##### **A. All FDA-Approved Indications (must meet all):**

1. Prescribed for one of the following conditions (a-m):
  - a. Allergic (atopic dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness);
  - b. Dermatologic (bullous dermatitis herpetiformis, contact dermatitis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme [Stevens-Johnson syndrome]);
  - c. Endocrine (congenital adrenal hyperplasia, hypercalcemia of malignancy, nonsuppurative thyroiditis, primary or secondary adrenocortical insufficiency);
  - d. Gastrointestinal (Crohn's Disease, ulcerative colitis);
  - e. Hematologic (acquired [autoimmune] hemolytic anemia, Diamond-Blackfan anemia, idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, secondary thrombocytopenia in adults);
  - f. Neoplastic (acute leukemia, aggressive lymphomas);
  - g. Nervous system (acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury);
  - h. Ophthalmic (sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical steroids);

- i. Acute or chronic solid organ rejection;
  - j. Pulmonary (acute exacerbations of chronic obstructive pulmonary disease [COPD], allergic bronchopulmonary aspergillosis, aspiration pneumonitis, asthma, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate chemotherapy, hypersensitivity pneumonitis, idiopathic bronchiolitis obliterans with organizing pneumonia, idiopathic eosinophilic pneumonias, idiopathic pulmonary fibrosis, pneumocystis carinii pneumonia [PCP] associated with hypoxemia occurring in an human immunodeficiency virus [HIV]-positive individual who is also under treatment with appropriate anti-PCP antibiotics, symptomatic sarcoidosis);
  - k. Renal (to induce a diuresis or remission of proteinuria in nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus);
  - l. Rheumatologic (acute gouty arthritis, exacerbation, or maintenance therapy in cases of: ankylosing spondylitis, dermatomyositis/polymyositis, polymyalgia rheumatica, psoriatic arthritis, relapsing polychondritis, rheumatoid arthritis [including juvenile rheumatoid arthritis], Sjogren's syndrome, systemic lupus erythematosus, vasculitis);
  - m. Infectious diseases (trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block);
2. Member must use generic immediate-release oral prednisone, unless contraindicated or clinically significant adverse effects are experienced.

**Approval duration: 12 months or duration of request, whichever is less**

**B. Other diagnoses/indications (must meet 1 or 2):**

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
  - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial; or
  - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial.

**II. Continued Therapy**

**A. All FDA-Approved Indications (must meet all):**

1. Member meets one of the following (a or b):
  - a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
  - b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B*);

2. Member is responding positively to therapy.

**Approval duration: 12 months or duration of request, whichever is less**

**B. Other diagnoses/indications (must meet 1 or 2):**

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
  - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial; or
  - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial.

**III. Diagnoses/Indications for which coverage is NOT authorized:**

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off-label use policy – CP.CPA.09 or evidence of coverage documents.

**IV. Appendices/General Information**

*Appendix A: Abbreviation/Acronym Key:*

COPD: chronic obstructive pulmonary disease

FDA: Food and Drug Administration

HIV: human immunodeficiency virus

PCP: pneumocystis carinii pneumonia

*Appendix B: Therapeutic Alternatives:*

*This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.*

<b>Drug Name</b>	<b>Dosing Regimen</b>	<b>Dose Limit/Maximum Dose</b>
immediate-release prednisone	Varies based on condition being treated	Varies

*Therapeutic alternatives are listed as Brand name<sup>®</sup> (generic) when the drug is available by brand name only and generic (Brand name<sup>®</sup>) when the drug is available by both brand and generic.*

*Appendix C: Contraindications/Boxed Warnings*

- Contraindication(s): known hypersensitivity to prednisone or any excipients in the formulation
- Boxed warning(s): none reported

**V. Dosage and Administration**

Indication	Dosing Regimen	Maximum Dose
All FDA-approved indications	<p>Patients on immediate-release prednisone, prednisolone, or methylprednisolone should be switched to Rayos at an equivalent dose based on relative potency</p> <p>Initial dose: 5 mg to 60 mg PO QD depending on the specific disease entity being treated.</p> <p>Maintenance dose: Use lowest dosage that will maintain an adequate clinical response.</p>	Varies

**VI. Product Availability**

Delayed-release tablets: 1 mg, 2 mg, 5 mg

**VII. References**

1. Rayos Prescribing Information. Deerfield, IL: Horizon Therapeutics USA, Inc.; March 2024. Available at: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2024/202020s0131bl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202020s0131bl.pdf). Accessed July 25, 2025.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
4Q 2021 annual review: added symptomatic sarcoidosis in the approval criteria per FDA indication; modified 'medical justification' language for redirection to member 'must use'; references reviewed and updated.	08.12.21	11.21
Revised approval duration for Commercial line of business from length of benefit to 12 months or duration of request, whichever is less	09.27.21	02.22
4Q 2022 annual review: no significant changes; references reviewed and updated. Template changes applied to other diagnoses/indications and continued therapy section.	07.22.22	11.22
4Q 2023 annual review: no significant changes; references reviewed and updated.	08.11.23	11.23
4Q 2024 annual review: no significant changes; references reviewed and updated.	08.02.24	11.24
4Q 2025 annual review: no significant changes; references reviewed and updated.	07.25.25	11.25

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and

accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright

**CLINICAL POLICY**  
Prednisone Delayed-Release



or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.